Theravance

Theravance appoints Michael W. Aguiar as president, CEO

Friday, August 8, 2014 12:29 PM

Theravance has appointed Michael W. Aguiar as president and CEO effective August 15, and as a member of the board of directors effective immediately. Aguiar plans to continue to as Theravance's senior vice president and chief financial officer until his replacement is identified and appointed. 

More... »

Quest Diagnostics

Theravance to split into two companies: R&D and royalty management

Thursday, May 8, 2014 01:21 PM

Biopharmaceutical company Theravance has announced it will split into two independent, publicly traded companies via a stock dividend on May 15.

More... »


Elan announces transactions to transform the company

Wednesday, May 22, 2013 10:42 AM

Elan, a biotechnology company based in Ireland, announced a series of transactions designed to decisively transform and advance the company. Upon shareholder approval, the totality of these strategically driven decisions, in addition to the Theravance royalty participation agreement, the dividend pass through, and the completed Tysabri transaction, will form a dynamic and unique business foundation for Elan in the years ahead.

More... »

FDA approves GSK’s Breo Ellipta to treat COPD

Friday, May 17, 2013 01:25 PM

The FDA has approved GlaxoSmithKline and Theravance’s Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also approved to reduce exacerbations of COPD in patients with a history of exacerbations. 

More... »

Elan CEO says $1 billion royalty deal with Theravance a unique opportunity

Tuesday, May 14, 2013 01:12 PM

Elan has announced a royalty agreement with Theravance, by which Elan will make a one-time cash payment of $1 billion to Theravance in exchange for a 21% participation interest in the potential future royalty payments from four respiratory programs for which Theravance has partnered with GlaxoSmithKline, when and if received by Theravance.

More... »

Theravance, Alfa Wassermann to develop and commercialize velusetrag for gastroparesis

Thursday, October 4, 2012 11:28 AM

Theravance, a biopharmaceutical company based in San Franciso, and Alfa Wassermann, a pharmaceutical company based on West Caldwell, N.J., have entered into an exclusive development and commercialization agreement in certain countries for velusetrag, Theravance's investigational 5-HT4 agonist in development for gastrointestinal motility disorders.

More... »

GSK, Theravance report positive results from four phase III COPD studies

Monday, July 2, 2012 03:09 PM

GlaxoSmithKline and Theravance, a biopharmaceutical company based in San Francisco, issued results from four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with chronic obstructive pulmonary disease (COPD).

More... »


CWWeekly

May 26

inVentiv Health aims to help sponsors prepare for new E.U. regulations on observational studies

ACRP partners with CRO Analytics to measure investigative sites' views of clinical trial quality

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs